nach oben

Erschienen in:

08.11.2016 | Original Article

Idiopathic Non-histaminergic Angioedema: Successful Treatment with Omalizumab in Five Patients

verfasst von: Charles Faisant, Aurélie Du Thanh, Catherine Mansard, Alban Deroux, Isabelle Boccon-Gibod, Laurence Bouillet

Erschienen in: Journal of Clinical Immunology | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Idiopathic non-histaminergic acquired angioedema (InH-AAE) is a rare disease characterized by AE resistant to antihistamines and a chronic course. We report five new cases of InH-AAE (two women and three men) with a rapid and dramatic response to the anti-immunoglobulin-E antibody omalizumab. In our literature review, we found 13 other relevant cases with a good response to this treatment. Overall, in 6 out of 18 patients, the doses of omalizumab required to prevent recurrences of attacks were higher than the licensed dose for chronic urticaria. No significant adverse effects have been reported.

Kaplan AP, Greaves MW. Angioedema. J Am Acad Dermatol. 2005;53:373–88.CrossRefPubMed

Bork K. Angioedema. Immunol Allergy Clin N Am. 2014;34(1):23–31.CrossRef

Grattan C, Sabroe R, Greaves M. Chronic urticaria. J Am Acad Dermatol. 2002;46:645–57.CrossRefPubMed

Greaves MW. Pathology and classification of urticaria. Immunol Allergy Clin N Am. 2014;34(1):1–9. doi:10.1016/j.iac.2013.07.009.CrossRef

Greaves M. Chronic urticaria. J Allergy Clin Immunol. 2000;105(4):664–72.CrossRefPubMed

Cicardi M, Aberer W, Banerji A, Bas M, Bernstein JA, Bork K, et al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy. 2014.

Mansi M, Zanichelli A, Coerezza A, Suffritti C, Wu MA, Vacchini R, et al. Presentation, diagnosis and treatment of angioedema without wheals: a retrospective analysis of a cohort of 1058 patients. J Intern Med. 2015;277(5):585–93.CrossRefPubMed

Zuberbier T, Aberer W, Asero R, BindslevJensen C, Brzoza Z, Canonica G, et al. The EAACI/GA(2)LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014;69:868–87.CrossRefPubMed

Maurer M, Rosen K, Hsieh H, Saini S, Grattan C, Gimenez-Arnau A, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368:924–35.CrossRefPubMed

10.

Saini S, Rosen K, Hsieh H, Wong D, Conner E, Kaplan A, et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine refractory chronic idiopathic urticaria. J Allergy Clin Immunol. 2011;128:567–573 e561.CrossRefPubMed

11.

Kaplan A, Ledford D, Ashby M, Canvin J, Zazzali J, Conner E, et al. Omalizumab in patients with symptomatic chronic idiopathic/ spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol. 2013;132:101–9.CrossRefPubMed

12.

Cugno M, Nussberger J, Cicardi M, Agostoni A. Bradykinin and the pathophysiology of angioedema. Int Immunopharmacol. 2003;3:311–7.CrossRefPubMed

13.

Colas C, Montoiro R, Fraj J, Garces M, Cubero JL, Caballero T. Nonhistaminergic idiopathic angioedema: clinical response to icatibant. J Investig Allergol Clin Immunol. 2012;22:520–1.PubMed

14.

Azofra J, Díaz C, Antépara I, Jaúregui I, Soriano A, Ferrer M. Positive response to omalizumab in patients with acquired idiopathic nonhistaminergic angioedema. Ann Allergy Asthma Immunol. 2015;114(5):418–9.e1.CrossRefPubMed

15.

Ozturk AB, Kocaturk E. Omalizumab in recurring larynx angioedema: a case report. Asia Pac Allergy. 2014;4(2):129–30.CrossRefPubMedPubMedCentral

16.

Sands MF, Blume JW, Schwartz SA. Successful treatment of 3 patients with recurrent idiopathic angioedema with omalizumab. J Allergy Clin Immunol. 2007;120(4):979–81.CrossRefPubMed

17.

Shroba J, Hanson J, Portnoy J. Current treatment options for idiopathic angioedema. Ann Allergy Asthma Immunol. 2015;115(5):429–33.CrossRefPubMed

18.

Wintenberger C, Boccon-Gibod I, Launay D, Fain O, Kanny G, Jeandel PY, et al. Tranexamic acid as maintenance treatment for non-histaminergic angioedema: analysis of efficacy and safety in 37 patients. Clin Exp Immunol. 2014;178(1):112–7.CrossRefPubMedPubMedCentral

19.

Asero R, Tedeschi A, Cugno M. Heparin and tranexamic acid therapy may be effective in treatment-resistant chronic urticaria with elevated d-dimer: a pilot study. Int Arch Allergy Immunol. 2010;152:384–9.CrossRefPubMed

20.

Shedden C, Highet AS. Delayed pressure urticaria controlled by tranexamic acid. Clin Exp Dermatol. 2006;31(2):295–6.CrossRefPubMed

21.

von Websky A, Reich K, Steinkraus V, Breuer K. Complete remission of severe chronic recurrent angioedema of unknown cause with omalizumab. J Dtsch Dermatol Ges. 2013;11(7):677–8.CrossRef

22.

Muñoz JP, Casado AF, Taboada AC, Campos Muñoz L, Bran EL. Successful treatment of refractory idiopathic angioedema with omalizumab: review of the literature and function of IgE in angioedema. Clin Exp Dermatol. 2015.

23.

Faisant C, Boccon-Gibod I, Mansard C, Dumestre Perard C, Pralong P, Chatain C, et al. Idiopathic histaminergic angioedema without wheals: a case series of 31 patients. Clin Exp Immunol. 2016.

24.

Beck LA, Marcotto GV, MacGlashan Jr D, Togias A, Saini S. Omalizumab-induced reductions in mast cell FceRI expression and function. J Allergy Clin Immunol. 2004;114:527–30.CrossRefPubMed

25.

Chang TW, Chen C, Lin CJ, Metz M, Church MK, Maurer M. The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria. J Allergy Clin Immunol. 2015;135(2):337–42.CrossRefPubMed

Titel: Idiopathic Non-histaminergic Angioedema: Successful Treatment with Omalizumab in Five Patients
verfasst von: Charles Faisant
Aurélie Du Thanh
Catherine Mansard
Alban Deroux
Isabelle Boccon-Gibod
Laurence Bouillet
Publikationsdatum: 08.11.2016
Verlag: Springer US
Erschienen in: Journal of Clinical Immunology / Ausgabe 1/2017
Print ISSN: 0271-9142
Elektronische ISSN: 1573-2592
DOI: https://doi.org/10.1007/s10875-016-0345-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

20.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Idiopathic Non-histaminergic Angioedema: Successful Treatment with Omalizumab in Five Patients

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2017

OL-EDA-ID Syndrome: a Novel Hypomorphic NEMO Mutation Associated with a Severe Clinical Presentation and Transient HLH

Large Deletion of MAGT1 Gene in a Patient with Classic Kaposi Sarcoma, CD4 Lymphopenia, and EBV Infection

Hematopoietic Stem Cell Transplantation for XIAP Deficiency in Japan

Comments on J Clin Immunol (2014) 34:633–641 DOI 10.1007/s10875-014-0061-0

Primary Immunodeficiency Classification on Smartphone

Targeted Sequencing and Immunological Analysis Reveal the Involvement of Primary Immunodeficiency Genes in Pediatric IBD: a Japanese Multicenter Study

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Update Innere Medizin